Intrarenal Microvasculature in ADPKD

Mayo Clinic

Status

Active, not recruiting

Conditions

Autosomal Dominant Polycystic Kidney Disease

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT05288998

1R21DK129886-01 (U.S. NIH Grant/Contract)

21-005117

Details and patient eligibility

About

The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and healthy volunteers.

Full description

An intact intrarenal microcirculation is vital to preserving normal kidney function, and microvascular dysfunction, damage, and loss are known to contribute to renal function decline. In ADPKD, extensive vascular remodeling has been proposed to play an important role in its progression. However, microvascular analyses in rodents and humans with ADPKD have been performed ex vivo or in vitro and from kidneys removed at the time of renal failure due to the invasive nature and additional limitations of the currently available techniques. A non-invasive and direct method to assess the intrarenal microvasculature is needed to improve early detection and gauge the progression of microvascular alterations and monitor the success of therapeutic approaches.

Current imaging modalities, such as micro-computed tomography, magnetic resonance imaging, and contrast-enhanced ultrasound, have attempted to provide a non-invasive assessment of the intrarenal microvasculature in pre-clinical models of kidney diseases. However, each of these modalities has important limitations when translating into humans, including high cost, requiring long imaging times, using nephrotoxic contrast agents, radiation exposure, low spatial resolution, and poor reproducibility.

Super-resolution ultrasound (SRU) imaging is among the most rapidly advancing imaging techniques introduced to overcome the limitation of the inherent spatial resolution of ultrasound. With the use of non-nephrotoxic contrast microbubbles to break the diffraction limit of ultrasound, and the introduction of ultrasound localization microscopy which utilizes ultrafast frame rate imaging to reconstruct a super-resolved composite image, SRU has provided a paradigm-shifting tool for structural and functional evaluation of tissue microvasculature. However, in vivo, human imaging, and kidney imaging pose significant organ depth challenges (which results in ultrasound signals with lower signal-to-noise ratio) and physiologic and operator-induced motion (which reduces the available data accumulation time). Our team recently implemented advanced filtering and microbubble localization and tracking techniques to overcome these limitations, which extract only microbubble signals and reliably pinpoint the center of each microbubble from the extracted signals.

The investigators' broad objective is to deploy and evaluate the use of SRU imaging coupled with advanced post-processing techniques to assess the intrarenal microvasculature in patients with early ADPKD and healthy volunteers.

Participants in this study will have a renal ultrasound to determine intrarenal microvascular parameters, and an abdominal MRI to determine the patient's total kidney volume (TKV), and additional vascular parameters. In addition, participants will have a blood and a urine sample collected to determine biomarkers of endothelial function and injury.

Enrollment

34 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (Patients with ADPKD):

Male and female subjects 18 - 40 years of age, inclusive
Previous diagnosis of ADPKD (based on Ravine et al. criteria)
Class 1 according to imaging classification
Estimated GFR> 90 mL/min/m2 (CKD-Epi equation)
Ability to provide written, informed consent

Inclusion Criteria (Healthy Volunteers):

Male and female subjects 18 - 40 years of age, inclusive
Estimated GFR> 90 mL/min/m2 (CKD-Epi equation)
Ability to provide written, informed consent

Exclusion Criteria (Patients with ADPKD):

Class 2 according to imaging classification
A concomitant systemic disease affecting the kidney (e.g., lupus, hepatitis B or C, amyloidosis)
Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics).
Predicted urine protein excretion in urinalysis >1 g/24 hrs.
Subjects having contraindications to or interference with MRI assessments. [For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.].
History of hypersensitivity allergic reactions to ultrasound contrast agents
High-risk cardiac disease (such as unstable hospital in-patients or ICU patients
Patients that are part of an interventional study or are taking tolvaptan
Female subjects that are pregnant

Exclusion Criteria (Healthy Volunteers):

Family and/or personal history of kidney disease
Concomitant systemic disease that may affect the kidney
Diabetes mellitus
Predicted urine protein excretion in >1 g/24 hrs, and or Abnormal urinalysis
Pregnant or lactating women
Subjects having contraindications to or interference with MRI assessments. [For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.].
History of hypersensitivity allergic reactions to ultrasound contrast agents
High risk cardiac disease (such as unstable hospital in-patients or ICU patients